Streetbeat News

Stock Prices

BCRX

BioCryst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 Orladeyo revenue guidance above estimates.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 6:34 pm

AGEN

BMY

MRK

RHHBY

Bristol Myers Squibb (BMY) has terminated its license, development, and commercialization agreement with Agenus Inc (AGEN) for the cancer drug AGEN1777. This decision is part of a broader strategic realignment. The termination will be effective from January 26, 2025. The news follows recent failures of similar TIGIT drugs from Roche (RHHBY) and Merck (MRK). AGEN's stock dropped 7.10% following the announcement.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 6:31 pm

SEM

Select Medical Holdings (NYSE:SEM) has seen a 13.49% increase in its short percent of float, now at 3.87%. This indicates a rise in bearish sentiment, although it remains below the peer group average of 6.51%. Traders should be aware of the increased short interest.

Portfolio Pulse from Benzinga Insights

August 05, 2024 | 6:30 pm

HWM

Howmet Aerospace (NYSE:HWM) has significantly outperformed the market over the past 5 years, delivering an average annual return of 35.06%. A $100 investment in HWM 5 years ago would now be worth $445.77. The company's market capitalization is currently $35.46 billion.

Portfolio Pulse from Benzinga Insights

August 05, 2024 | 6:30 pm

POOL

Pool Corporation (NASDAQ:POOL) has significantly outperformed the market over the past 15 years, delivering an average annual return of 19.89%. A $1000 investment in POOL 15 years ago would be worth $14,884.89 today. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

August 05, 2024 | 6:30 pm

MRNA

Moderna shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform and lowered its price target from $125 to $90.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 6:28 pm

AZN

MRK

NUVB

PFE

Nuvation Bio Inc. (NYSE:NUVB) has decided to halt the development of its BD2-selective BET inhibitor, NUV-868, after analyzing Phase 1 data. The company will not proceed with Phase 2 studies and is evaluating future steps for the program. NUVB stock fell 7.41% following the announcement.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 6:27 pm

MRK

Goldman Sachs discussed with Merck's President of Human Health International, Joe Romanelli, about Gardasil's performance and future outlook in China. Despite challenges in the Chinese vaccine market and operational issues with partner Zhifei, Merck remains confident in achieving over $11 billion in Gardasil sales by 2030. Goldman Sachs reiterates a Buy rating on Merck.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 6:25 pm

ITA

MISL

SPR

Boeing shares are trading lower as executives from Boeing and Spirit AeroSystems are set to testify at an NTSB hearing regarding a Boeing 737-9 MAX incident. Despite recent challenges, Goldman Sachs remains optimistic about Boeing's future cash flow and production rates, reiterating a Buy rating but lowering the price target. Boeing's stock has declined 30% in the past year.

Portfolio Pulse from Lekha Gupta

August 05, 2024 | 6:24 pm

OPEN

Opendoor Technologies (NYSE:OPEN) has seen a 5.94% increase in its short percent of float, now at 15.33%. This indicates a bearish sentiment among investors. The company's short interest is higher than its peers, which average 5.39%. It would take traders 5.22 days to cover their short positions.

Portfolio Pulse from Benzinga Insights

August 05, 2024 | 6:15 pm